Editor's note

This ExpertREACT article was originally published on 1 July 2008. Epidemiological data and pipeline positions described reflect the state of knowledge at that date.

RSV in the elderly: an underappreciated burden

Respiratory syncytial virus (RSV, Paramyxoviridae) is best known as the number one cause of lower respiratory tract infection (LRTI) in infants and young children worldwide, but it also causes serious complications in the elderly and immunocompromised. Each year RSV accounts for approximately 9,000 deaths and 177,000 hospital admissions in US adults aged 65 years and older. The WHO estimated 64 million global RSV cases and 160,000 deaths annually as of 2003. An estimated 14.5 million US elderly adults were at risk of RSV-related hospitalisation - a figure that brought RSV's adult burden into sharp relief alongside its more widely publicised paediatric impact. In healthy adults RSV typically caused a mild upper respiratory illness, but in elderly patients, those with chronic lung disease (COPD, asthma) and the severely immunocompromised (including bone marrow transplant recipients), RSV could progress to lower respiratory tract illness with significant mortality.

Current treatment options for RSV infection were limited. The inhalable antiviral ribavirin (Virazole) had not met expectations in terms of efficacy and convenience. In pre-term infants (under 36 weeks gestation) and those with congenital heart or lung disease, palivizumab (Synagis) - a monoclonal antibody licensed by the FDA in 1998 - had demonstrated in two pivotal trials a reduction in the risk of RSV hospitalisation by targeting the F-glycoprotein. However, palivizumab's high cost and requirement for monthly administration limited its use to the highest-risk paediatric patients, and it had no role in adult or elderly RSV prevention.

RSV US elderly burden (annually)
9,000 deaths
Estimated annual RSV-related deaths in US adults aged 65+, plus 177,000 hospitalisations; approximately 14.5m US elderly at risk

Vaccine design challenges and the adult opportunity

VacZine Analytics argued that manufacturers developing RSV vaccines should design strategies from the outset to address both the paediatric and elderly populations, rather than treating the adult indication as a secondary consideration. Historical experience with a formalin-inactivated RSV vaccine in the 1960s - which caused enhanced disease rather than protection - had created long-standing scientific caution around RSV vaccine development. By 2008 this caution was being systematically addressed through understanding of the molecular mechanisms involved and the development of antigen candidates including recombinant F-protein approaches. VacZine Analytics viewed the elderly RSV market as a potentially very significant commercial opportunity alongside any paediatric RSV vaccination programme.